- 1 <u>Title</u>
- 2 The Colloido-Osmotic Pressure as a useful biomarker of fatal outcome in pregnant
- 3 COVID-19 patients
- 4 <u>Running title</u>
- 5 Fatal outcome in Pregnant women with COVID-19
- 6 Authors and institutional affiliations
- 7 B. Zavala-Barrios^{1**}, A. Cérbulo-Vázquez^{2**}, M. García-Espinosa³, F. Caldiño-Soto⁴,
- 8 Ruth L. Madera Sandoval⁹, L.A. Ramírez-García⁵, I.C. Eláceo-Fernández⁸, O. Moreno-
- 9 Álvarez⁶, G.M.L. Guerrero-Avendaño⁷, J.C. Briones-Garduño⁸*
- 10 ¹Subdirección de Apoyo al Diagnóstico y Tratamiento, ²Servicio de Medicina
- 11 Genómica, ⁷Dirección General, ⁸Servicio de Ginecologia y Obstetricia, Hospital
- 12 General de México "Dr. Eduardo Liceaga". Ciudad de Mexico, Mexico
- ¹³ ³Servicio de complicaciones de la segunda mitad del embarazo, ⁴División Obstetricia.
- ⁵Dirección Médica, ⁶Dirección General. UMAE Hospital de Gineco-Obstetricia No. 4
- 15 "Dr. Luis Castelazo Ayala". Instituto Mexicano del Seguro Social (IMSS). Ciudad de
- 16 Mexico, Mexico.
- ⁹Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades,
- 18 Centro Médico Nacional Siglo XXI. IMSS. Ciudad de México, México.
- 19 *Corresponding author
- 20 J.C. Briones-Garduño
- 21 E-mail: drcarlosbriones@yahoo.com.mx
- 22 Cel. 52 55 4458 4640
- 23 **These authors contributed equally
- 24 Keywords: COVID-19, pregnancy, USG, Doppler, Blood Gas Test. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Background: Pregnancy was considering a health condition that could support high 27 severity in COVID-19, among others the cardiologic and respiratory systems express 28 some physiologic change in the pregnant women and could specially affected in COVID-29 19. Pregnant women characteristically have an increase volume of blood, with a higher 30 cardiac output and lower peripheral vascular resistance, these could be negative affected 31 by hypoalbuminemia frequently observed in COVID-19. Then, an early recognition of 32 hypoalbuminemia in pregnant women with COVID-19 would help us to predict fatal 33 outcome. Objective: We conduct a study to analyzed the demographic, clinical, blood gas 34 test results, laboratory and ultrasonographic doppler data in pregnant women with 35 COVID-19 that demand medical attention for labor. Study design: Ninety-two pregnant women with COVID-19 were included in our study from may 30th 2020 to august 12th 36 37 2022, and data was analyzed in survival and fatal outcome patients. Normality test were 38 applied to data and parametric or non-parametric test were used to determine statistical 39 difference between or among data. Results: Demographic and clinical data were quite 40 similar between survival and fatal outcome pregnant patients with COVID-19. Also, blood gas test shown similar results among groups (asymptomatic, mild, or severe 41 42 patients who survive COVID-19 or fatal outcome patients). We observed that serum 43 albumin was consistently low in pregnant patients with fatal outcome by COVID-19, then 44 based on Total Protein concentration in serum we calculated the colloido-osmotic 45 pressure and we evaluate its utility as predictor of fatal outcome. ROC analysis and 46 Kaplan-Meier of survival curves suggest that the colloido-osmotic pressure could be a 47 potential predictor. Also, we observed an association of low colloido-osmotic pressure 48 and low amniotic fluid index. Conclusion: Our study suggests that early evaluation of

- 49 pregnant with COVID-19 must include the calculation of colloido-osmotic pressure and
- 50 the doppler analysis to early recognition of fatal outcome in pregnant women with
- 51 COVID-19.
- 52

53 Introduction

54 Since 2019 the high number of persons with SARS-CoV-2 result in a pandemic 55 emergency with loss of millions of lives ¹. Fatal outcome by COVID-19 has been 56 associated with certain comorbidities such as obesity or hypertension among others, also 57 pregnant women may experience a high fatality rate probably because a high 58 susceptibility to inflammation². During pregnancy, the immune response develops an 59 immunological tolerance and a high level of regulation to inflammatory response, 60 however this delicate balance could negative affected in pregnant women with COVID-61 19³. Also, a profound physiologic regulation in other systems can be observed in 62 pregnancy, which includes the circulatory and respiratory systems ^{4,5}. Pregnant women 63 characteristically have an increase volume of blood, with a higher cardiac output and 64 lower peripheral vascular resistance, also, pregnant women tend to develop a respiratory 65 alkalosis with pH between normal limits, and all these characteristics could be negative 66 affected by COVID-19.

67 COVID-19-associated deaths during pregnancy was increasing worldwide, Karimi et al 68 reported 153 deaths out of 11758 pregnant and postpartum women with COVID-19 69 (1.3%). However, the mortality rate is differential between high- or middle-income 70 countries. The high-income countries show a mortality rate about 0.19%, while in middle-71 income countries was as high as 8.51% ⁶. In Mexico, from April 2022 to August 2021, 72 389 maternal deaths by COVID-19 were recorded in a population of 20329 pregnant and 73 postpartum women (1.9%) ⁷.

Demographic data in pregnant women with COVID-19 shows that they are frequently older than 31 years old ⁸, with a Body Mass Index >30, multiple pregnancy and hypertension ⁸⁻¹⁰. In addition, some social condition in mild-income countries could lead

to undernutrition especially in pregnant women, and leading to poor immune response
against COVID-19 ^{11,12}. Undernutrition could be recognized by low serum albumin,
which is a good predictor for negative outcomes after surgeries ¹³, or infection disease as
COVID-19 ¹⁴.

81 In addition, certain laboratory parameters in pregnant women with COVID-19 are useful to detect high risk of fatal outcome, among these parameters the leucocyte count ¹⁵, 82 platelet count ¹⁶ or neutrophil-lymphocyte ratio (NLR)¹⁷ had been reported. Likewise, the 83 84 evaluation of arterial blood gas parameters is essential to evaluate pregnant women with 85 COVID-19, however, a low number of studies shows the arterial blood gas test in 86 pregnant women with COVID-19. Also, it has been reported that some chemistry 87 parameters can be useful for early detection of severe COVID-19, among them the serum values of creatinine ¹⁸, procalcitonin (PCT) ¹⁹ or albumin ²⁰ had been reported, however, 88 89 poor analysis is available for pregnant women with COVID-19. Specially the 90 hypoalbuminemia could result in negative changes in pregnant women because it led to 91 a low Colloido-Osmotic Pressure (cCOP). This is a pressure exerted by the protein on the 92 capillary membranes, and could be calculated using the formula 1 of Landis-93 Pappenheimer, and fatal outcome in trauma patients is frequently observed in patients 94 with values as low as <15 mmHg of cCOP²¹. A low cCOP could limit the maternal-fetal 95 interchange, compromise the placental perfusion and altering the microvasculature in 96 chorionic villi ²², however, all these changes could closely monitored by doppler 97 ultrasonography, following the blood flow in the: Umbilical artery (UA), uterine artery 98 (UAT), Fetal Middle Cerebral Artery (FMCA), or Amniotic Fluid Index (AFI). Until 99 now, there are few studies that include the ultrasonographic evaluation in pregnant

100 women with COVID-19, and the few reported no differences between SARS-CoV-2-

101 positive pregnant women and controls ²³.

102 Our study analyzed demographic, clinical, laboratory, arterial blood gas test and doppler 103 data in pregnant women with COVID-19 who survive or got a fatal outcome, the results 104 suggest that cCOP can early detect pregnant women with COVID-19 with high 105 probability of having a fatal outcome.

106 Material and methods

107 Patients

108 This study was conducted by the "Servicio de Ginecología y Obstetricia" at the Hospital 109 General de Mexico "Dr. Eduardo Liceaga" (HGM, Research project: DI/20112/04/45), 110 and the Servicio de complicaciones de la segunda mitad del embarazo, División 111 Obstetricia, UMAE Hospital de Gineco-Obstetricia No. 4 "Dr. Luis Castelazo Ayala" 112 (UMAE HGO-4 IMSS. Research project: R-2020-785-095). After obtaining a signed 113 informed consent letter, ninety-two women were enrolled and assigned to one of three 114 groups: a) asymptomatic, n=20, b) mild COVID-19, n=56, c) severe COVID-19, n=16, 115 then 6 patients in the severe COVID-19 group got a fatal outcome and was analyzed as a 116 different group. The COVID-19 diagnosis was based on clinical characteristics and 117 positive RT-PCR test for SARS-CoV-2 or radiographic images compatible with COVID-118 19 disease. Demographic, Clinical and Comorbidities features were recorded.

119 Blood sample collection

120 Our study is in accordance with the World Medical Association's Declaration of Helsinki.

121 After the patients signed the informed consent letter, blood specimens were collected in

122 silicone-coated tubes (EDTA or heparinized tubes, BD Vacutainer, N. J, USA), samples

123 were processed immediately after collection.

124 Arterial Blood Gas test

Heparin blood samples were obtained and blood gas analysis was performed on an
ABL90 Flex Plus blood gas analyzer (Radiometer Medical ApS, Bronshoj, Denmark)
within 30 min of collect.

128 Doppler test

Doppler analysis was as D'Antonio reported ²⁴, we performed the analysis using a 129 130 Samsung HS40 (Samsung Healthcare, N.J., USA) or a Chison EBit 50 (Chison, Jiangsu, 131 China) ultrasound machines. Data was recorded during fetal quiescence, without fetal 132 tachycardia, with the insonation angle kept as close to 0° as possible. FMCA was 133 examined at the point at which it passes the sphenoid wing, close to the circle of Willis, 134 and the UA was examined at a free loop of the umbilical cord. To record the UAT 135 Doppler, the transducer was placed over the iliac fossa and the course of the uterine 136 arteries was followed from the lateral pelvic wall across external iliac artery using color 137 Doppler. Pulsed Doppler was then applied 1 cm medial to the crossover point. When three 138 similar consecutive waveforms were obtained, the PI was measured, and the mean value of the left and right uterine artery PI calculated. 139

140 *Statistical analysis*

Statistical analysis was performed using GraphPad Prism® version 7 software (GraphPad
Software, San Diego, CA, USA) and the R i386 3.5.2 terminal (Microsoft corp., Boston,
MA, USA.). Categorical variables were expressed as percentages (%), and compared by
Fisher's exact test. Non-parametric ANOVA (Kruskal–Wallis test) with Dunn's posttest

145 was applied. Spearman correlation for interest variables was implemented. A p<0.05 was 146 considered statistically significant.

147 **Results**

148 Ninety-two pregnant patients with COVID-19 was attended in the HGM and reviewed 149 with coauthors in the UMAE HGO-4 IMSS, from may 30th 2020 to august 12th 2022. All 150 patients got an RT-PCR+ for SARS-CoV-2 or radiographic imagen diagnostic for SARS-151 CoV-2 infection. Twenty of the ninety-two pregnant patients in labor without any clinical 152 sign of COVID-19 got a positive result for SARS-CoV-2 PCR test, these asymptomatic 153 patients were included in our study. Table 1 show clinical and laboratory characteristics. 154 no statistical difference was observed for age, body mass index, gestational age, trimester 155 of gestation, weight newborn, or Apgar score among the groups, however, prolonged 156 stays in hospital were observed in severe or fatal outcome patients with COVID-19 than 157 in asymptomatic patients positive for SARS-CoV-2. Also, we observed a similar number 158 of leucocytes and platelets among groups (Table 1). However, the percentage of PMN 159 was higher in patients with severe COVID-19 than in asymptomatic pregnant women. 160 Table 2 shows the results of arterial blood gas test. No statistical significance was observed in pH, PaO₂, saturation of O₂ or lactate among groups, however, severe patients 161 162 show a higher CO₂ value than mild patients (p=0.005), also, the BE was lower in the mild 163 group than in fatal outcome patients (p=0.02). Results in Table 2 shows that pregnant 164 women developing a respiratory alkalosis probably due by hyperventilation, this

respiratory condition is quite frequent in pregnant patients and pH values are in normallimits.

Regarding chemistry parameters, we observed that creatinine and D-Dimer concentration were similar among groups (Table 3), however, procalcitonin was higher in severe COVID-19 than in asymptomatic patients (p=0.040). Also, the asymptomatic patients show the highest serum albumin concentration, while the lowest serum albumin was in fatal outcome pregnant women with COVID-19 (Table 3).

- 172 Fig. 1A shows the cCOP in mild-severe COVID-19 pregnant women is higher than in
- 173 fatal outcome pregnant women with COVID-19. Moreover, moderate correlation (r=
- 174 0.45) among cCOP and amniotic fluid index, was observed (fig.1B) in patients with mild,
- 175 severe and fatal outcome.
- Also, the ROC curve analysis show that the AUC was 53.2%, and the optimal cutoff was calculated in accordance with Youden index 15.7, with a confidence interval of 77.8%, 57.1%. Also, a survival curve of cCOP was analyzed. Kaplan-Meier of survival curves were made according to the optimal cutoff, and hazard ratio expressed in percentage, p<0.05. The median days of survival was 340 for the lower risk group and a 31% of risk for the patients with value greater than 15.7. Fig. 2 shows the ultrasonographic analysis in survivor pregnant women with COVID-19
- 183 or asymptomatic patients SARS-CoV-2 positive. Similar results were observed for UA,
- UAT, and FMCA among groups, however, the amniotic fluid index show statistical difference, were asymptomatic patients show a higher index than in severe COVID-19 patients (p=0.01) or higher index in mild COVID-19 patients than in severe COVID-19 patients (p=0.02).

188 **Discussion**

189 Principal Findings

190 The early recognition of severe or critical COVID-19 in pregnant women would help us 191 to get a lower maternal mortality by COVID-19, or predict fatal outcome in pregnant 192 women with COVID-19. Our study shows that long stay in hospital (media=14-15 days) 193 is characteristic of patients with severe COVID-19 or fatal outcome (Table 1). We also 194 observed that arterial blood gas test was quite similar among pregnant women with 195 COVID-19 even in those who got a fatal outcome (Table 2). In agreement with the 196 literature hypoalbuminemia was noted specially in patients with severe COVID-19 or 197 those who got fatal outcome (Table 3). We calculated the Colloido-osmotic pressure in 198 mild and severe COVID-19 and compared with patients with fatal outcome, a significant 199 difference was observed between those groups, and association between cCOP and 200 amniotic fluid index was observed (Figure 1). Unfortunately, a doppler test was not 201 applied on patients with fatal outcome by COVID-19, however, we observed that the 202 amniotic fluid index was lower according to severity of COVID-19 (Figure 2).

203 Results

204 Several studies show the mean of age of pregnant women with COVID-19 is around 30 205 years old ^{8,15,25-31}, and most pregnant women with COVID-19 were aged between 20 to 206 39 years ⁹, our study also show that pregnant women with COVID-19 or asymptomatic 207 patients were around 30 years old (Table 1). Comorbidities as obesity has been associated to suffer severe COVID-19 in pregnant women⁸, and been in a higher risk for maternal 208 209 death ³², and some studies show that BMI over 30 is frequently observed in pregnant 210 women COVID-19 patients ^{28,31}, our study also observed this condition (Table 1). The 211 most of literature show that pregnant women with COVID-19 have a mean of gestational 212 age around 30 weeks ^{28,29}, or higher gestational age than 30 weeks ^{26,27}, as we expect the 213 most of maternal death in pregnant women with COVID-19 has been observed in the third trimester of pregnancy, however, other studies did not show a high number of fatal 214

outcomes by COVID-19 in the third trimester ³³⁻³⁶. Maternal mortality could be as low as 0.2 to 2% ^{10,37-39}, or as high as 10 to 20% ^{6,40-42} according with low- or middle-income ⁴²⁻⁴⁴. Our study shows similar data for gestational age, fatal outcome by trimester and maternal mortality as a middle-income country, these observation in a sense validate our study and could help to increase the number of observations for pregnant women with COVID-19 in the very first wave when collection of data was so difficult.

221 Early evaluation of blood gas test in pregnant women with COVID-19 seems to be critical 222 and could help to recognize severity. Both alkalosis and acidosis were observed in 223 patients with COVID-19 in general population, and alkalosis was observed in 54.3% of 224 the subjects ⁴⁵. Also, ketoacidosis has been reported in pregnant women with COVID-19 225 which is associated with diabetes, hyperglycemia and ketosis ^{46,47}. However, our result 226 did not show great differences among groups, indicating that blood gas parameters was 227 not altered even with variants of SARS-CoV-2 that express high maternal mortality. More 228 observations must do it to clarify this observation.

229 Blood cell count had been analyzed in patients with COVID-19, some authors show that 230 white blood cell count is higher in pregnant than in non-pregnant women with COVID-231 19²⁷, however, other studies show that leucocytosis was not observed in pregnant women with COVID-19^{27,35}, in contrast, some pregnant women with COVID-19 show 232 233 lymphopenia ⁴⁸. In agreement with Wang Z et. al. and Yan J et. al. we did not observe 234 great differences in leucocytes counts among the groups. Finally, has been reported that 235 a lower platelet count is observed in patients with severe COVID-19^{16,18}, while other 236 study show that the platelet count was similar in pregnant women with and without 237 SARS-CoV-2 infection ⁴⁹. In agreement with Covali R et. al. we did not observed 238 difference in the platelet count of pregnant women with COVID-19, no difference was

observed among groups by severity or fatal outcome, this is probably because the
relatively small number of patients. More studies are necessary to clarify if low platelet
count is a good predictor of fatal outcome in pregnant women.

242 Shmakov RG et. al. shows a similar D-Dimer concentration among asymptomatic, mild, moderate and severe COVID-19 in pregnant women ²⁸, and our study agrees with this 243 244 observation. Another potential biomarker is the PCT, however, the value of this 245 biomarker to predict severity in COVID-19 show some contradictory results in general 246 population ¹⁹, and in pregnant women with COVI-19, PCT levels was similar between pregnant and non-pregnant women with COVID-19^{41,50}, while some other study show a 247 248 difference between them ²⁷. Because the PCT was similar among mild, moderate and 249 severe COVID-19 in pregnant women ²⁸, the result suggest that PCT is not able to 250 discriminate the mild from severe COVID-19 in pregnant women, our study agrees with 251 this observation, we observed that the highest PCT concentration was in the mild cases, 252 in the mild group we observed patients with PCT values quite similar to severe COVID-253 19 patients (range 0.010-11.0 ng/mL) and a subgroup of mild COVID-19 patients with 254 high values of PCT (918.0-5227.0 ng/mL), suggesting that this second subgroup got a 255 bacterial infection, however, we could not get a positive bacterial culture on them, 256 interestingly, none of this potential over infected patients got a fatal outcome, suggesting 257 that even in the case of double infection the immune system of pregnant women will be 258 sufficient to solve the infection challenge.

Hypoalbuminemia has been associated to disease severity in COVID-19 ^{20,28,51}, the expression of hypoalbuminemia on admission is more frequent in non-survivors than survivors, and could be useful as an early predictor of mortality in COVID-19 ⁵²⁻⁵⁴. In contrast, a high level of albumin on admission is associated with a lower risk of Acute

263 Respiratory Distress Syndrome and admission to ICU ⁵³. Lower albumin concentration 264 was reported in pregnant than in non-pregnant women with COVID-19 without fatal 265 outcome ²⁷, our results show that a hypoalbuminemia as low as 2.5 could result in low 266 colloido-osmotic pressure and finally a fatal outcome. The colloido-osmotic pressure is 267 easily evaluated among patients, and our study propose its routine analysis to predict fatal 268 outcome in pregnant women with COVID-19. Moreover, low cCOP in COVID-19 could 269 lead to impaired placental perfusion. It has been reported that SARS-CoV-2 infection 270 does not affect the blood flow in the umbilical vein 55, also, in pregnant women recovered from COVID-19 the pulsatility and resistance indices of umbilical and uterine artery show 271 272 a significant increase than in controls ⁵⁶. In contrast, Soto-Torres et. al. report that Doppler 273 evaluation was similar between pregnant women with SARS-CoV-2 infection and 274 controls ²³. In agreement with Soto-Torres et. al. we observed that the umbilical artery, 275 uterine artery, and fetal middle cerebral artery the blood flow were similar in pregnant 276 and non-pregnant COVID-19 women, however, we observed that the Amniotic Fluid 277 Index was lower in severe than in mild or asymptomatic COVID-19 patients, this lower 278 amniotic fluid index in severe COVID-19 patients could expressed or been the Fetal 279 Inflammatory Response Syndrome by viral infection.

- 280
- 281 *Clinical implications*

Two conditions could explain the high maternal mortality in our hospital a) because we are in a middle-income country and b) because our hospital is a national reference center. We were able to classify our patients in asymptomatic, mild, and severe COVID-19 patients; however, some clinical characteristics of our patients were quite similar among groups as age, BMI, gestational age, weight newborn, Apgar score etc. indicating that those characteristics have low value to early recognize patients with high potential for a

288 fatal outcome. Also, our study show that pregnant women tend to respiratory alkalosis 289 that is not necessarily deteriorated by COVID-19. Despite a limited respiratory condition 290 in pregnant women, it seems that gas test in pregnant women with COVID-19 is similar 291 than in women in general population with COVID-19. Some other laboratory analysis as 292 the blood count was also analyzed, we did not observe leukocytosis or lymphopenia in 293 pregnant women with COVID-19, and no association with severity was observed, 294 probably because a small number of patients in our study. We observed the highest 295 neutrophilia in pregnant women with severe COVID-19, however, neutropenia and not 296 neutrophilia was observed in pregnant women with COVID-19 and fatal outcome. 297 Neutrophils are important innate cells that participate in many mechanisms related with 298 inflammation, its high or low number in pregnant women with COVID-19 seems to be 299 important for limit the infection, however, we need more analysis in pregnant women to 300 clarify if neutropenia and neutrophilia are supporter of pathophysiology in COVID-19. 301 Our results suggest that Basic Doppler evaluation could be useful to early recognition of 302 severe COVID-19 in pregnant women.

303

304 Research implications

We do not know when the next pandemic comes, but patients with comorbidities or 305 306 special conditions as pregnancy will be affected. Due the complex condition in prenatal 307 surveillance, labor and postpartum period during pandemic for COVID-19 many 308 opportunities of do deeper analysis of data o searching for a no-conventional assessment 309 were lost, and data in pregnant women with COVID-19 is scarce. Medical attention of 310 pregnant patients must include a holistic view, with strict attention to ethical and patient's 311 rights, and then collect any data that potentially could help to understand the new disease 312 like COVID-19 and minimize the fatal outcomes.

2	1	2
Э	T	2

314 Strengths and limitations

315 Our study has some limitations and strengths, the number of observations is relatively 316 low (n=92) with six fatal outcomes included (6.5%), because early in the pandemic a 317 medical treatment was not established and medical support was apply after some days of 318 the initial COVID-19 symptoms a high percentage of fatal outcome was observed, 319 however, our study also show demographic, clinical and laboratory data observed at the 320 very early time (in the second wave) of pandemic of COVID-19 in Mexico, and when 321 vaccination was not available, these conditions could help us to understand the natural 322 progression in pregnant women with COVID-19. 323 324 **Conclusions** A high number of comorbidities is observed in COVID-19 patients with high severity. 325 326 and also the pregnancy could allow a severe presentation of COVID-19. However, the 327 frequency of severe cases in pregnant women with COVID-19 is similar than in general population ^{15,41,57}, due to the pandemic condition many studies in pregnant women with 328 329 COVID-19 show missing or not collected data, our data show that hypoalbuminemia and 330 the cCOP could help to early recognize patients with high risk of fatal outcome, more 331 studies are necessary to know if pregnancy must not take as a comorbidity that increase

the risk of severe COVID-19.

333

334 <u>Contributors</u>

BZB, ACV and JCBG conceived and designed the study and contributed to data analysis.
BZB and ACV wrote the first version of manuscript. MGE, FCS, LARG, RLMS, JCBG,
OMA, and GMLGA contributed to a critical revision of the report. MGE, FCS, LARG,
ICEF, JCBG, BZB, and OMA contributed to the clinical evaluation of patients and
supervision of medical treatments and patient care. RLMS contributed to do the statistical
analysis and graph data. All authors reviewed the final version. JCBG reviewed and
approved the final version.

- 342
- 343 Acknowledgments

344 The authors extend gratitude to the staff at Gynecology & Obstetrics Department in the 345 General Hospital of Mexico "Dr. Eduardo Liceaga" and Gynecology & Obstetric 346 Hospital No. 4 UMAE "Dr. Luis Castelazo Avala". 347 348 Declaration of interests 349 All authors declare no competing interests. 350 351 References 352 353 WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ 1. 354 2. Adab P, Haroon S, O'Hara ME, Jordan RE. Comorbidities and covid-19. BMJ. 355 Jun 15 2022;377:01431. doi:10.1136/bmj.01431 356 Cerbulo-Vazquez A, Garcia-Espinosa M, Briones-Garduno JC, et al. The 3. 357 percentage of CD39+ monocytes is higher in pregnant COVID-19+ patients than in 358 COVID-19+ PLoS nonpregnant patients. One. 2022;17(7):e0264566. 359 doi:10.1371/journal.pone.0264566 360 Hegewald MJ, Crapo RO. Respiratory physiology in pregnancy. Clin Chest Med. 4. 361 Mar 2011;32(1):1-13. doi:10.1016/j.ccm.2010.11.001 362 LoMauro A, Aliverti A. Respiratory physiology in pregnancy and assessment of 5. 363 pulmonary function. Best Pract Res Clin *Obstet* Gynaecol. Jun 27 364 2022;doi:10.1016/j.bpobgyn.2022.05.007 Karimi L, Makvandi S, Vahedian-Azimi A, Sathyapalan T, Sahebkar A. Effect of 365 6. COVID-19 on Mortality of Pregnant and Postpartum Women: A Systematic Review and 366 367 Meta-Analysis. J Pregnancy. 2021;2021:8870129. doi:10.1155/2021/8870129 368 Epidemiología CNdEdGvSRDGd. Aviso 7. Epidemiologico COVID-19. 369 https://www.gob.mx > uploads > attachment > file 370 8. Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal 371 morbidities associated with COVID-19 in pregnant women in France: A national 372 retrospective cohort study. PLoS Med. Nov 2021;18(11):e1003857. 373 doi:10.1371/journal.pmed.1003857 374 Galang RR, Newton SM, Woodworth KR, et al. Risk Factors for Illness Severity 9. 375 Among Pregnant Women With Confirmed Severe Acute Respiratory Syndrome 376 Coronavirus 2 Infection-Surveillance for Emerging Threats to Mothers and Babies 377 Network, 22 State, Local, and Territorial Health Departments, 29 March 2020-5 March 378 2021. Clin Infect Dis. Jul 15 2021;73(Suppl 1):S17-S23. doi:10.1093/cid/ciab432 379 10. Overton EE, Goffman D, Friedman AM. The Epidemiology of COVID-19 in 380 Pregnancy. Clin Obstet Gvnecol. Mar 1 2022;65(1):110-122. 381 doi:10.1097/GRF.000000000000674 382 James PT, Ali Z, Armitage AE, et al. The Role of Nutrition in COVID-19 11. 383 Susceptibility and Severity of Disease: A Systematic Review. J Nutr. Jul 1 2021;151(7):1854-1878. doi:10.1093/jn/nxab059 384 385 Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. 12. 386 Semin Dial. Nov-Dec 2004;17(6):432-7. doi:10.1111/j.0894-0959.2004.17603.x 387 Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum 13. 388 albumin level as a predictor of operative mortality and morbidity: results from the 389 National VA Surgical Risk Study. Arch Surg. Jan 1999;134(1):36-42. 390 doi:10.1001/archsurg.134.1.36

Mentella MC, Scaldaferri F, Gasbarrini A, Miggiano GAD. The Role of Nutrition
in the COVID-19 Pandemic. *Nutrients*. Mar 27 2021;13(4)doi:10.3390/nu13041093

Amini Moghadam S, Dini P, Nassiri S, Motavaselian M, Hajibaba M, Sohrabi M.
Clinical features of pregnant women in Iran who died due to COVID-19. *Int J Gynaecol*

395 *Obstet*. Feb 2021;152(2):215-219. doi:10.1002/ijgo.13461

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe
coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*. Jul
2020;506:145-148. doi:10.1016/j.cca.2020.03.022

- 17. Lasser DM, Chervenak J, Moore RM, et al. Severity of COVID-19 Respiratory
 Complications during Pregnancy are Associated with Degree of Lymphopenia and
 Neutrophil to Lymphocyte Ratio on Presentation: A Multicenter Cohort Study. *Am J Perinatol.* Oct 2021;38(12):1236-1243. doi:10.1055/s-0041-1732421
- Tufa A, Gebremariam TH, Manyazewal T, et al. Limited value of neutrophil-tolymphocyte ratio and serum creatinine as point-of-care biomarkers of disease severity
 and infection mortality in patients hospitalized with COVID-19. *PLoS One.*2022;17(10):e0275391. doi:10.1371/journal.pone.0275391
- 407 19. Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing
 408 antibiotic treatment: an update with a focus on COVID-19. *Crit Rev Clin Lab Sci.* Jan
 409 2022;59(1):54-65. doi:10.1080/10408363.2021.1975637
- 410 20. Johnson AS, Winlow W. COVID-19 vulnerabilities are intensified by declining
 411 human serum albumin levels. *Exp Physiol.* Jul 2022;107(7):674-682.
 412 doi:10.1113/EP089703
- 413 21. Alberto Basilio Olivares JCB, Jesús Antonio Jiménez Origel,, Ponce MADdL. La
 414 presión coloidosmótica (PCO) como indicador
- 415 pronóstico en trauma. Reporte preliminar. Rev Asoc Mex Med Crit y Ter Int.
 416 2012;26(4):230-233.
- 417 22. Acharya G, Sonesson SE, Flo K, Rasanen J, Odibo A. Hemodynamic aspects of
 418 normal human feto-placental (umbilical) circulation. *Acta Obstet Gynecol Scand*. Jun
 419 2016;95(6):672-82. doi:10.1111/aogs.12919
- Soto-Torres E, Hernandez-Andrade E, Huntley E, Mendez-Figueroa H, Blackwell
 SC. Ultrasound and Doppler findings in pregnant women with SARS-CoV-2 infection. *Ultrasound Obstet Gynecol.* Jul 2021;58(1):111-120. doi:10.1002/uog.23642
- 423 D'Antonio F, Rizzo G, Gustapane S, et al. Diagnostic accuracy of Doppler 24. 424 ultrasound in predicting perinatal outcome in pregnancies at term: A prospective 425 longitudinal study. Acta **Obstet** Gynecol Scand. Jan 2020;99(1):42-47. 426 doi:10.1111/aogs.13705
- 25. Dawood FS, Varner M, Tita A, et al. Incidence and Clinical Characteristics of and
 Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
 Infection Among Pregnant Individuals in the United States. *Clin Infect Dis.* Jul 6
 2022;74(12):2218-2226. doi:10.1093/cid/ciab713
- 26. Zhang J, Zhang Y, Ma Y, et al. The associated factors of cesarean section during
 432 COVID-19 pandemic: a cross-sectional study in nine cities of China. *Environ Health Prev*433 *Med.* Oct 10 2020;25(1):60. doi:10.1186/s12199-020-00899-w
- 434 27. Wang Z, Wang Z, Xiong G. Clinical characteristics and laboratory results of 435 pregnant women with COVID-19 in Wuhan, China. *Int J Gynaecol Obstet*. Sep 436 2020;150(3):312-317. doi:10.1002/ijgo.13265

437 28. Shmakov RG, Prikhodko A, Polushkina E, et al. Clinical course of novel COVID438 19 infection in pregnant women. *J Matern Fetal Neonatal Med.* Dec 2022;35(23):44314437. doi:10.1080/14767058.2020.1850683

440 Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and 29. 441 critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort 442 study. J**Obstet** Gvnecol MFM. Aug 2020;2(3):100134. Am 443 doi:10.1016/j.ajogmf.2020.100134

444 30. Capobianco G, Saderi L, Aliberti S, et al. COVID-19 in pregnant women: A 445 systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. Sep 446 2020;252:543-558. doi:10.1016/j.ejogrb.2020.07.006

447 31. Afshar Y, Gaw SL, Flaherman VJ, et al. Clinical Presentation of Coronavirus
448 Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. *Obstet Gynecol.*449 Dec 2020;136(6):1117-1125. doi:10.1097/AOG.00000000004178

450 32. Mendez-Dominguez N, Santos-Zaldivar K, Gomez-Carro S, Datta-Banik S,
451 Carrillo G. Maternal mortality during the COVID-19 pandemic in Mexico: a preliminary
452 analysis during the first year. *BMC Public Health*. Jul 2 2021;21(1):1297.
453 doi:10.1186/s12889-021-11325-3

Gupta V, Yadav Y, Sharma R, Mishra M, Ambedkar D, Gupta V. Maternal and
Perinatal Outcomes of Hospitalized COVID-19 Positive Pregnant Women. *Cureus*. Feb
2022;14(2):e21817. doi:10.7759/cureus.21817

457 34. DeBolt CA, Bianco A, Limaye MA, et al. Pregnant women with severe or critical
458 coronavirus disease 2019 have increased composite morbidity compared with
459 nonpregnant matched controls. *Am J Obstet Gynecol*. May 2021;224(5):510 e1-510 e12.
460 doi:10.1016/j.ajog.2020.11.022

461 35. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report
462 based on 116 cases. *Am J Obstet Gynecol*. Jul 2020;223(1):111 e1-111 e14.
463 doi:10.1016/j.ajog.2020.04.014

464 36. London V, McLaren R, Jr., Atallah F, et al. The Relationship between Status at
465 Presentation and Outcomes among Pregnant Women with COVID-19. *Am J Perinatol.*466 Aug 2020;37(10):991-994. doi:10.1055/s-0040-1712164

467 37. Metz TD, Clifton RG, Hughes BL, et al. Association of SARS-CoV-2 Infection
468 With Serious Maternal Morbidity and Mortality From Obstetric Complications. *JAMA*.
469 Feb 22 2022;327(8):748-759. doi:10.1001/jama.2022.1190

470 38. Borges Charepe N, Queiros A, Alves MJ, et al. One Year of COVID-19 in
471 Pregnancy: A National Wide Collaborative Study. *Acta Med Port.* May 2
472 2022;35(5):357-366. doi:10.20344/amp.16574

Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effect of coronavirus
disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic
review. *Ultrasound Obstet Gynecol.* Jul 2020;56(1):15-27. doi:10.1002/uog.22088

476 40. Leung C, Simoes ESAC, Oliveira EA. Are in-hospital COVID-19-related
477 mortality and morbidity in pregnancy associated with gestational age? *Ultrasound Obstet*478 *Gynecol.* Aug 2022;60(2):234-242. doi:10.1002/uog.24931

479 41. Khoiwal K, Ravi AK, Arora S, et al. Impact of Pregnancy on Susceptibility and
480 Severity of COVID-19: A Hospital-Based Prospective Observational Study. *Cureus*. Apr
481 2022;14(4):e24281. doi:10.7759/cureus.24281

482 42. Nakamura-Pereira M, Betina Andreucci C, de Oliveira Menezes M, Knobel R,
483 Takemoto MLS. Worldwide maternal deaths due to COVID-19: A brief review. Int J
484 Gurgagel Obstat. Oct 2020;151(1):148-150. doi:10.1002/jige.12328

484 *Gynaecol Obstet*. Oct 2020;151(1):148-150. doi:10.1002/ijgo.13328

485 43. Takemoto MLS, Menezes MO, Andreucci CB, et al. Maternal mortality and
486 COVID-19. *J Matern Fetal Neonatal Med.* Jun 2022;35(12):2355-2361.
487 doi:10.1080/14767058.2020.1786056

488 Maza-Arnedo F, Paternina-Caicedo A, Sosa CG, et al. Maternal mortality linked 44. 489 to COVID-19 in Latin America: Results from a multi-country collaborative database of 490 447 deaths. Lancet Reg Health Am. Aug 2022;12:100269. 491 doi:10.1016/j.lana.2022.100269

492 45. Sanghani H, Bansal S, Parmar V, Shah R. Study of Arterial Blood Gas Analysis
493 in Moderate-to-Severe COVID-19 Patients. *Cureus*. Jul 2022;14(7):e26715.
494 doi:10.7759/cureus.26715

495 46. van Amesfoort JE, Werter DE, Painter RC, Hermans FJR. Severe metabolic
496 ketoacidosis as a primary manifestation of SARS-CoV-2 infection in non-diabetic
497 pregnancy. *BMJ Case Rep.* Apr 19 2021;14(4)doi:10.1136/bcr-2021-241745

47. Pikovsky M, Tan MY, Ahmed A, Sykes L, Agha-Jaffar R, Yu CKH. Euglycaemic
499 ketoacidosis in pregnant women with COVID-19: two case reports. *BMC Pregnancy*500 *Childbirth*. Jun 16 2021;21(1):427. doi:10.1186/s12884-021-03928-w

50148.Al-Saadi E, Abdulnabi MA. Hematological changes associated with COVID-19502infection. J Clin Lab Anal. Jan 2022;36(1):e24064. doi:10.1002/jcla.24064

49. Covali R, Socolov D, Socolov R, et al. Complete Blood Count Peculiarities in
Pregnant SARS-CoV-2-Infected Patients at Term: A Cohort Study. *Diagnostics (Basel)*.
505 Dec 30 2021;12(1)doi:10.3390/diagnostics12010080

506 50. Asghar MS, Siddiqui MA, Iqbal S, et al. COVID-19 infection among pregnant 507 and non-pregnant women: Comparison of biochemical markers and outcomes during 508 COVID-19 pandemic, A retrospective cohort study. *Ann Med Surg (Lond)*. Apr 509 2022;76:103527. doi:10.1016/j.amsu.2022.103527

51. Xu Y, Yang H, Wang J, et al. Serum Albumin Levels are a Predictor of COVID19 Patient Prognosis: Evidence from a Single Cohort in Chongqing, China. *Int J Gen*512 *Med.* 2021;14:2785-2797. doi:10.2147/IJGM.S312521

513 52. Viana-Llamas MC, Arroyo-Espliguero R, Silva-Obregon JA, et al. 514 Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality 515 and adverse events. A retrospective observational study. *Med Clin (Barc)*. May 7 516 2021;156(9):428-436. doi:10.1016/j.medcli.2020.12.018

517 53. Kheir M, Saleem F, Wang C, Mann A, Chua J. Higher albumin levels on 518 admission predict better prognosis in patients with confirmed COVID-19. *PLoS One*. 519 2021;16(3):e0248358. doi:10.1371/journal.pone.0248358

520 54. Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of 521 COVID-19 independent of age and co-morbidity. *J Med Virol*. Oct 2020;92(10):2152-522 2158. doi:10.1002/jmv.26003

523 55. Rizzo G, Mappa I, Pietrolucci ME, Lu JLA, Makatsarya A, D'Antonio F. Effect 524 of SARS-CoV-2 infection on fetal umbilical vein flow and cardiac function: a prospective 525 study. *J Perinat Med*. May 25 2022;50(4):398-403. doi:10.1515/jpm-2021-0657

526 56. Anuk AT, Tanacan A, Yetiskin FDY, et al. Doppler assessment of the fetus in 527 pregnant women recovered from COVID-19. *J Obstet Gynaecol Res.* May 528 2021;47(5):1757-1762. doi:10.1111/jog.14726

529 57. Hessami K, Homayoon N, Hashemi A, Vafaei H, Kasraeian M, Asadi N. COVID-530 19 and maternal, fetal and neonatal mortality: a systematic review. *J Matern Fetal* 531 *Neonatal Med*. Aug 2022;35(15):2936-2941. doi:10.1080/14767058.2020.1806817

532

533

Table 1. Clinical and laboratory characteristics of pregnant women with COVID 19 Survivor

		Survivor			
	Asymptomatic	Mild	Severe	Fatal	р
	(n=20) ^a	(n=56) ^b	(n=10) °	Outcome	
				(n=6) ^d	
Age (years)	29.1±4.7	28.8±6.8	31.8±4.7	30.5±4.0	ns
BMI	30.3±6.2	30.5±5.9	28.3±3.9	25.9±4.3	ns
Gestational	35.1±7.4	32.5±8.0	30.6±6.7	28.5±6.1	ns
age (Weeks)					
1 st trimester	1	2	0	0	
2 nd trimester	1	6	2	2	ns
3 rd trimester	18	47	7	4	
Weight	2869±754	2730±605	2038±550	1817±814	ns
Newborn					
(gr)					
Apgar score	7.5±1.5	7.9±1.0	4.6±4.1	7.5±1.0	ns
Hospital	2.8±1.6	5.4±5.8	14.3±8.0	15.6±9.7	a vs c
days					<0.0001
					a vs d
					0.004
					b vs c
					0.0009
Leucocytes	9.2±2.1	7.9±2.7	9.9±4.1	10.2±4.4	ns
(10 ³ xµL)					
PLT	259±90.7	222.8±87.4	217.9±47.5	211.7±73.1	ns
(10 ³ xµL)					

0.048	PMN (%)	75.3±8.2	73.7±18.0	85.6±7.6	56.6±41.7	a vs c
						0.048

1

536 BMI; Body Mass Index. Kruskal–Wallis test and Dunn's multiple comparisons test. Significant p < 0.05. 537 Mean±SD.

538

539

540 Table 2. Arterial Blood Gas parameters of pregnant women with COVID-19

		Survivor			
	Asymptomatic	Mild	Severe	Fatal Outcome	р
	(n=20) ^a	(n=56) ^b	(n=10) °	(n=6) ^d	
рН	7.3±0.04	7.3±0.03	7.3±0.08	7.4±0.08	ns
CO ₂	32.0±2.3	27.8±4.0	34.3±6.9	31.4±6.4	b vs c
					0.005
O ₂	66.1±31.1	78.3±16.9	64.2±15.2	65.1±21.3	ns
Sat O ₂	79.8±22.6	85.6±22.4	84.0±19.5	83.8±16.6	ns
Lactate	2.1±0.8	10.0±26	0.7±5.4	2.4±1.5	ns
BE	-6.8±3.3	-6.6±3.5	-4.5±3.6	-2.9±1.3	b vs d
					0.023

541 BE; Basic excess. Kruskal–Wallis test and Dunn's multiple comparisons test. Significant p < 0.05. 542 Mean±SD.

543

544Table 3. Clinical chemistry parameters of pregnant women with COVID-19

Survivor


	Asymptomatic	Mild	Severe	Fatal	р
	(n=20) ^a	(n=56) ^b	(n=10) °	Outcome	
				(n=6) ^d	
Creatinine	0.5±0.08	0.2±1.7	0.8±0.8	0.5±0.2	ns
(mg/dL)					
D-Dimer	2261±1254	2022±2035	3303±3825	11360±17192	ns
(ng/mL)					

РСТ	0.07 ± 0.06	496.2±1129	1.3±2.7	0.3±0.1	a vs c
(ng/mL)					0.040
Albumin	3.2±0.2	3.1±0.4	2.7±0.3	2.6±0.1	a vs c
(g/dL)					0.021
					a vs d
					0.005
					b vs c
					0.036
					b vs d
					0.010

545 PCT; Procalcitonin. Kruskal–Wallis test and Dunn's multiple comparisons test. Significant p < 0.05. 546 Mean±SD.

547

548 Figure legends



549

Fig. 1. Colloido-Osmotic Pressure calculated in severe and fatal outcome pregnant women with COVID-19. The cCOP was calculated as described in the methods. A) Pregnant women with Mild-Severe COVID-19 have a higher cCOP than in pregnant women with fatal outcome, B) Sperman correlation between cCOP and amniotic fluid index. The correlation value (among mild, severe COVID-19 and fatal outcome patients) suggesting a medium correlation, p= 0.22. The results are expressed as the mean±SD. Significance value was p<0.05. U Mann-Whitney tests were calculated.




Fig. 2. Maternal-fetal Doppler test in pregnant women with COVID-19. Pregnant women were tested by USG as described in the methods. Doppler analysis is shown for A) Umbilical artery, B) Uterine artery, C) Fetal middle cerebral artery, and D) Amniotic fluid index. Dash line indicate normal limits. The results are expressed as the mean \pm SD. Significance value was p<0.05. Kruskal–Wallis and Dunn's multiple comparisons tests were calculated.

557